Spondyloarthritis & psoriatic arthritis

Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab

Arthritis Res TherPublished Prospective cohort study

An erratum to this article was published (Arthritis Res Ther, 17 Jul 2026 ↗)

Authors' conclusion

A 1-year secukinumab-based treat-to-target strategy in axSpA patients provided rapid and sustained clinical improvement, MRI-inflammation reduction and structural remodelling. BMI, sex, HLA-B27 and clinical/MRI disease activity predicted clinical and MRI-remission.

Study context

Population
Biologic-naïve patients with active axial spondyloarthritis (axSpA)54 completed w56
Participants
90 patients
Outcome
Clinical remission (ASDAS < 1.3)
Follow-up
Week 56
Methodological detailsinvestigator-initiated, multicentre, treat-to-target, single-arm, dose-escalation, multivariable logistic regression
  • Investigator-initiated
  • Multicentre
  • Treat-to-target
  • Single-arm
  • Dose-escalation
  • Multivariable logistic regression

Main finding

As reported in the abstract

Patients achieving w56 clinical remission

32

59%

Observational data: associations, not effects.

Further findings

Total MRI-inflammation (sacroiliac joint (SIJ) + spine), mean · week 0 to 56

Decreased from mean 39.0 to 6.7

MRI remission (SPARCC-SIJ ≤ 1 + CANDEN-spine ≤ 2) · week 56

Achieving w56 MRI remission
43%

Structural lesion remodelling on MRI · week 4 to 56

Evident by w4 and sustained through w56: erosion decreased, fat lesion and backfill increased, new bone formation/ankylosis unchanged
MRI-inflammation and structural lesion changes comparable irrespective of w56 clinical remission status and treatment at w56

Independent baseline predictors of remission

w16 clinical remission: ASDAS and BMI
w56 clinical remission: none
w16 MRI remission: female sex, lower MRI-inflammation and higher MRI-erosion score
w56 MRI remission: lower MRI-inflammation and HLA-B27 positivity
  • Multivariable logistic regression

Original publication

Clinical and MRI remission in axial spondyloarthritis: one-year outcomes and predictors from the TRACE treat-to-target study with secukinumab. Arthritis Res Ther. Published 25 April 2026. doi:10.1186/s13075-026-03816-8

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.